Health and Healthcare
Dendreon, When 200% Sales Growth Is Not Enough (DNDN)
Published:
Last Updated:
Dendreon Corporation (NASDAQ: DNDN) has reported its quarterly results and the reaction is a bit cool. This is growth of almost 200%, as net product revenue for the quarter was $82.0 million versus $27.0 million a year ago. The net loss in the first quarter was $103.9 million, or -$0.70 per share, and that is down from a net loss of $112.8 million a year ago. Excluding cash and noncash severance expenses, the report would have been for a net loss of $87.1 million, or -$0.59 per share.
Thomson Reuters has estimates of -$0.63 EPS and $81.23 million in sales. The company called this report as having exceeded its guidance of low single-digit quarter-over-quarter growth.
Dendreon had approximately $559.1 million in cash, cash equivalents and short-term and long-term investments as of March 31, down from $617.7 at the end of the December 31, 2011 period.
Without formal guidance, we cannot consider this report as “finished business” until that data is out.
Dendreon shares closed up 3.2% at $11.69 against a 52-week range of $6.46 to $42.87, and shares are down 7.3% at $10.82 in the after-hours session.
JON C. OGG
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.